33 results
424B3
BIAF
BioAffinity Technologies Inc
22 May 24
Prospectus supplement
4:00pm
and Taiwan, increasing economic uncertainty and inflationary pressures, and any consequent worsening of the global business and economic environment
424B3
BIAF
BioAffinity Technologies Inc
22 May 24
Prospectus supplement
4:00pm
economic uncertainty and inflationary pressures, and any consequent worsening of the global business and economic environment. New factors emerge from
424B3
BIAF
BioAffinity Technologies Inc
16 Apr 24
Prospectus supplement
7:19pm
pressures, and any consequent worsening of the global business and economic environment. New factors emerge from time to time, and it is not possible … of new technologies or those subject to clinical testing, and the competitive and regulatory environment in which we will operate. To date, we have
POS AM
BIAF
BioAffinity Technologies Inc
1 Apr 24
Prospectus update (post-effective amendment)
8:06pm
business and economic environment. New factors emerge from time to time, and it is not possible for us to predict all such factors. Should one or more … , and the competitive and regulatory environment in which we will operate. To date, we have generated revenue from a limited market launch of CyPath® Lung
8-K
EX-10.1
n57dn5chw 6aumsp
8 Mar 24
Entry into a Material Definitive Agreement
5:00pm
424B5
4t3kl liez
8 Mar 24
Prospectus supplement for primary offering
12:18pm
424B5
cxtlfj
7 Mar 24
Prospectus supplement for primary offering
9:57pm
424B5
9pr4z
28 Nov 23
Prospectus supplement for primary offering
4:00pm
S-3
w76 leu2wtnps
16 Nov 23
Shelf registration
5:23pm
8-K
EX-10.3
tefjm
20 Sep 23
Entry into a Material Definitive Agreement
4:52pm
8-K
EX-10.1
xin2hhetlwo
20 Sep 23
Entry into a Material Definitive Agreement
4:52pm
DRS
2dd1 v8cm
14 Aug 23
Draft registration statement
12:00am
10-K
i12417t6
31 Mar 23
Annual report
3:40pm
8-K
EX-99.1
hav3vjdlsr
12 Oct 22
Other Events
11:51am